Evidence map›Paper›PMID 39104661›Full record

ArticleVascular health and risk management2024

The Causal Effect of Serum Lipid Levels Mediated by Neuregulin 4 on the Risk of Four Atherosclerosis Subtypes: Evidence from Mendelian Randomization Analysis.

Longyi Zheng, Chengjing Zhang, Shichang Bu, Wencheng Guo, Tongtong Li, Ying Xu, Yunan Liu, Caimei Yuan, Chengwu Feng, Geng Zong and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vascular health and risk management, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Longyi Zheng *Department of Endocrinology, Changhai Hospital, Naval Medical University, Shanghai, People's Republic of China.
Chengjing Zhang *Department of Nutrition, Shanghai Eastern Hepatobiliary Surgery Hospital, Shanghai, People's Republic of China.
Shichang Bu *Department of Endocrinology, Changhai Hospital, Naval Medical University, Shanghai, People's Republic of China.
Wencheng Guo *Department of General Surgery and Vascular Surgery, Huashan Hospital, Fudan University, Shanghai, People's Republic of China.
Tongtong LiCAS Key Laboratory of Nutrition, Metabolism and Food Safety, Shanghai Institute of Nutrition and Health, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai, People's Republic of China.
Ying XuNational Center for Liver Cancer, Naval Medical University, Shanghai, People's Republic of China.
Yunan LiuCAS Key Laboratory of Nutrition, Metabolism and Food Safety, Shanghai Institute of Nutrition and Health, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai, People's Republic of China.
Caimei YuanCAS Key Laboratory of Nutrition, Metabolism and Food Safety, Shanghai Institute of Nutrition and Health, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai, People's Republic of China.
Chengwu FengCAS Key Laboratory of Nutrition, Metabolism and Food Safety, Shanghai Institute of Nutrition and Health, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai, People's Republic of China.
Geng ZongCAS Key Laboratory of Nutrition, Metabolism and Food Safety, Shanghai Institute of Nutrition and Health, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai, People's Republic of China.
Jingwen ZhuCAS Key Laboratory of Nutrition, Metabolism and Food Safety, Shanghai Institute of Nutrition and Health, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai, People's Republic of China.
Maoying XingNational Center for Liver Cancer, Naval Medical University, Shanghai, People's Republic of China.
Xin GengNational Center for Liver Cancer, Naval Medical University, Shanghai, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Neuregulin 4 (NRG4) was known to be associated with serum lipid levels and atherosclerosis. However, it is unknown whether the role of NRG4 in lipid homeostasis is causal to atherosclerosis and whether the effect is beneficial across different atherosclerosis subtypes. Methods: We investigated the causal role of the levels of serum low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol, and triglycerides regulated by NRG4 in subtypes of atherosclerosis through two sample Mendelian randomization. Aggregated genome-wide association study (GWAS) summary data for serum lipid level of 1.32 million individuals with European ancestry were obtained from the Global Lipids Genetics Consortium. GWAS summary data for four atherosclerosis subtypes (peripheral, coronary, cerebral and the other atherosclerosis) were obtained from FinnGen Consortium. Generalized inverse-variance-weighted Mendelian randomization and several sensitivity analyses were used to obtain the causal estimates. Results: A 1-SD genetically elevated LDL-C level mediated by NRG4 was validated to be nominally associated with the risk of peripheral atherosclerosis (log (odds ratio)= 4.14, 95% confidence interval 0.11 to 8.17, P = 0.04), and the other associations were not significant or could not be validated by sensitivity analyses. Conclusion: LDL-C lowering mediated by NRG4 is likely to prevent peripheral atherosclerosis.

Indexed as

AtherosclerosisBiomarkersCholesterol, HDLCholesterol, LDLGenetic Predisposition to DiseaseGenome-Wide Association StudyMendelian Randomization AnalysisNeuregulinsPhenotypePolymorphism, Single NucleotideTriglyceridesHumansRisk AssessmentRisk FactorsBiomarkersCholesterol, HDLCholesterol, LDLneuregulin-4NeuregulinsTriglyceridesatherosclerosislipidMendelian randomization analysisNRG4

Identifiers

PMID39104661
PMCPMC11299727

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.